Mercury Laboratories Limited (BOM:538964)

India flag India · Delayed Price · Currency is INR
801.65
-33.35 (-3.99%)
At close: Jul 27, 2026
Market Cap961.20M -6.9%
Revenue (ttm)737.65M -3.7%
Net Income41.64M +10.4%
EPS34.70 +10.5%
Shares Out 1.20M
PE Ratio23.09
Forward PEn/a
Dividend3.50 (0.44%)
Ex-Dividend DateSep 21, 2026
Volume401
Open799.95
Previous Close835.00
Day's Range788.05 - 826.00
52-Week Range620.55 - 976.00
Beta0.40
Analystsn/a
Price Targetn/a
Earnings DateJul 25, 2026

About Mercury Laboratories

Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-allergi... [Read more]

Industry Pharmaceutical Preparations
Founded 1962
Employees 503
Stock Exchange Bombay Stock Exchange
Ticker Symbol 538964
Full Company Profile

Financial Performance

In fiscal year 2026, Mercury Laboratories's revenue was 759.37 million, an increase of 1.11% compared to the previous year's 751.01 million. Earnings were 48.34 million, an increase of 53.71%.

Financial Statements